This page is intended for GB patients and members of the public.
If you have been treated with a Seqirus vaccine or are caring for someone who has and have a question or concern, we recommended that you discuss this in the first instance with your Healthcare Professional, as they are best-placed to support you.
GB licensed products
Cell based quadrivalent influenza vaccine ▼(surface antigen, inactivated)
▼These vaccines are subject to additional monitoring. This will allow quick identification of new safety information.
If you get any side effects or need support with your CSL Seqirus vaccines, talk to your doctor, pharmacist or nurse. This includes any possible side affects not listed in the package leaflet. You can also report side effects directly via the MHRA Yellow Card scheme.
GBR-FLU360-23-0022 October 2023
Our Customer Service Team is available 08.00 - 17.00 on business days
You are going to be redirected to an external website. We hope this link will be of interest to you but accept no liability in relation to the website or its content. CSL Seqirus cannot be held responsible for the accuracy and completeness of the information, or for any loss and damage that may arise from your use of this third-party site.
If you wish to carry on navigating to this site, click on Continue, if not click on Cancel to return to the previous page.